Glioblastoma  >>  Erbitux (cetuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
NCT00311857 / 2005-003911-63: Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

Unknown status
1/2
46
Europe
Cetuximab, Temozolomide, Radiation therapy
Heidelberg University, Merck KGaA, Darmstadt, Germany
Glioblastoma Multiforme
 
 

Download Options